P32/98: Antidiabetic Dipeptidyl-Peptidase IV Inhibitor

Drugs of the Future

Volumn 26, Issue 9, 2001, Pages 859-864

  Sorbera, L A ^a   Revel, L ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242432676     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.09.635893     Document Type: Article

References (19)

1. Schön, E., Born, I., Demuth, H.-U., Faust, J., Neubert, K., Steinmetzer, T., Barth, A., Ansorge, S. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe Seyler 1991, 372: 305-11.
2. Neubert, K., Born, I., Faust, J., Heins, J., Barth, A., Demuth, H.-U., Rahfeld, J.U., Steinmetzer, T. (Martin Luther Universität Halle-Wittenberg). DD 296075.
3. Prous Science Drug R&D Backgrounders: Diabetes mellitus (online publication). Updated July 20, 2001.
4. Hopsu-Havu, V.K., Sarimo, S.R. Purification and characterization of an aminopeptidase hydrolyzing glycyl-proline-naphthylamide. Hoppe Seylers Z Physiol Chem 1967, 348: 1540-50.
5. Gossrau, R. Peptidases II. Localization of dipeptidylpeptidase IV (DPP IV). Histochemical and biochemical study. Histochemistry 1979, 60: 231-48.
6. Walter, R., Simmons, W.H., Yoshimoto, T. Proline specific endo- and exopeptidases. Mol Cell Biochem 1980, 30: 111-27.
7. Brown, J.C., Dahl, M., Kwauk, S., McIntosh, C.H., Otte, S.C., Pederson, R.A. Actions of GIP. Peptides 1981, 2(Suppl. 2) 241-5.
8. Suzuki, S., Kawai, K., Ohashi, S., Mukai, H., Yamashita, K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 1989, 125: 3109-14.
9. Stöckel-Maschek, A., Stiebitz, B., Born, I., Faust, J., Mögelin, W., Neubert, K. Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition. Adv Exp Med Biol 2000, 477: 117-23.
10. Stöckel, A., Demuth, H.-U., Neubert, K. Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides. Pept Chem 1995 (Pub 1996): 709.
11. Pauly, R.P., Demuthn H.-U.., Rosche, F., Schmidt, J., White, H.A., Lynn, F., McIntosh, C.H., Pederson, R.A. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor lle-thiazolidide. Metab Clin Exp 1999, 48: 385-9.
12. Freyse, E.J., Knospe, S., Glund, K., Demuth, H.U. Dosage of a dipeptidyl peptidase IV (DP IV) inhibitor and timing of its administration to improve glucose tolerance in rats. Diabetes 1999, 48(Suppl. 1): Abst 1555.
13. Stocker, C., Wargent, E., Subramaniam, A., Demuth, H.U., Sennitt, M., Cawthorne, M.A. The dipeptidyl peptidase IV inhibitor P32/98 improves glucose tolerance in diabetic ZDF rats. Diabetes 2001, 50(Suppl. 2): Abst 2200-PO.
14. Freyse, E.-J., Berg, S., Glund, K., Heinke, P., Demuth, H.-U. Metabolic effects of subchronic oral application of the DPIV-inhibitor P32/98 and a P32/98-prodrug in diabetic Zucker rats (fa/fa). Diabetes 2001, 50(Suppl. 2): Abst 2162-PO.
15. Freyse, E.J., Berg, S., Heinke, P., McIntosh, C.H.S., Pederson. R.A., Glund, K., Demuth, H.-U. Glucose metabolism in diabetic Zucker rats (ZR) during chronic oral therapy by the DP IV inhibitor P32/98. Diabetes 2000, 49(Suppl. 1): Abst 1808-PO.
16. Pospisilik, J.A., Stafford, S., Demuth, H.-U., McIntosh, C.H.S., Pederson, R.A. Long-term DP IV inhibitor (P32/98) treatment causes sustained improvements in glucose tolerance, insulin sensitivity, and hyperinsulinemia in fa/fa Zucker rats. Diabetes 2001, 50(Suppl. 2): Abst 1291-PO.
17. Demuth, H.-U., Glund, K., Banke-Bochita, J., Rost, K.-L., Fischer, S., Hanefeld, M., McIntosh, C.H.S., Pederson, R.A. Dipeptidyl peptidase IV (DP IV)-modulation as treatment of impaired glucose tolerance and NIDDM. Regul Pept 2000, 94(1-3): 16.
18. Demuth, H.-U., Hoffmann, T., Glund, K., McIntosh, C.H.S., Pederson, R.A., Fuecker, K., Fischer, S., Hanefeld, M. Single dose treatment of type 2 diabetics by the DP IV-inhibitor P32/98. Diabetes Res Clin Pract 2000, 50(Suppl. 1): S386.
19. Merck & Co.,Inc. and Probiodrug GmbH sign exclusive worldwide licensing arrangement. Probiodrug Press Release December 11, 2000.